Skip to content

Integrated Biosciences

4 viewers · 30d

Total raised

$68.4M

+$68.4M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $68.4M
ROUNDS
1
INVESTORS
39
FOUNDED
2022
HQ
Redwood City, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
4

AI overview

Updated

Integrated Biosciences is a Redwood City, California biotechnology company discovering small-molecule therapeutics for age-related and cardiometabolic diseases. Its discovery engine combines proprietary optogenetic tools, differentiated aging datasets generated across cellular and whole-organism models, and machine learning that proposes and prioritizes drug hypotheses. The company was founded in 2022 by biophysicist Felix Wong and biology professor Max Wilson, with scientific roots in Jim Collins' lab at MIT. Its work has been published in Nature, Nature Aging and Cell, including a new class of antibiotics identified with its AI platform.

What sets it apart

Optogenetic screening gives tunable millisecond- and micron-level control over cellular stress pathways that conventional assays cannot address, producing high-fidelity proprietary datasets that make its AI models more predictive than models trained on public data.

Funding history

1 round
EquityJul 21, 2026
Form D
+$68.4M$68.4M total

Latest SEC filings

via EDGAR · CIK 0002148371
Form D · Jul 21, 2026NewView on EDGAR

Products

1 tracked

Optogenetic drug discovery platform

Drug discovery platform

An integrated discovery engine that pairs a first-of-its-kind optogenetic screening platform with novel chemistry tools and machine learning. Light-controlled activation of cellular stress and aging pathways generates high-throughput, high-fidelity datasets; AI models trained on those datasets propose molecules, which are then validated experimentally and fed back into the platform.

  • Optogenetic control of biological pathways with millisecond and micron resolution
  • Proprietary aging datasets across cellular and whole-organism models
  • Machine learning models that propose and rank drug hypotheses
  • Novel chemistry tooling for small-molecule optimization